Spectrum announced that it has submitted a New Drug Application (NDA) for Belinostat (PXD 101), a pan-histone deacetylase (HDAC) inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).

RELATED: Oncology Resource Center

Belinostat is different from other HDAC inhibitors in that it selectively inhibits a single class of HDAC enzymes by inhibition of all 3 classes of the zinc-dependent HDAC enzymes (Class I, Class II and Class IV). Its anticancer effect is thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis, inhibition of angiogenesis, induction of differentiation, and the activity in tumors that had become resistant to anticancer agents such as the platinums, taxanes, and topoisomerase II inhibitors.

Belinostat is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers.

For more information call (877) 387-4538 or visit SpectrumPharm.com.